November 28, 2021

Medical Trend

Medical News and Medical Resources

Tumor vaccine UV1: 50% of patients survive for more than 5 years!

Tumor vaccine UV1: 50% of patients survive for more than 5 years!

Tumor vaccine UV1: 50% of patients survive for more than 5 years!



 

Tumor vaccine UV1: 50% of patients survive for more than 5 years!

50% of patients survive for more than 5 years! Tumor vaccine UV1 has obtained FDA fast track qualification. Which anti-cancer vaccines are worthy of attention?

Among the top ten scientific breakthroughs of the year ranked by the “Science” magazine in 2013, immunotherapy topped the list. In recent years, immunotherapy has always been a hot spot in the field of tumor treatment research at home and abroad, which can be called a revolutionary breakthrough.

 

Among them, immune checkpoint inhibitor therapy (such as CTLA-4 monoclonal antibody, PD-1/PD-L1 monoclonal antibody, etc.) has shined in the fields of melanoma, lung cancer, kidney cancer, squamous cell carcinoma and liver cancer, but has not Not all cancer patients respond to immune checkpoint inhibitors.

 

Speaking of vaccines, everyone is not unfamiliar, except for the common hepatitis B vaccine and influenza vaccine, the new coronavirus vaccine we have been vaccinated up to now. In fact, cancer vaccines are also a form of immunotherapy, which can prevent the development of cancer or kill existing tumors by stimulating or restoring the body’s own immune system. There are special proteins on the surface of cancer cells. By targeting these proteins, the immune system can specifically eliminate cancer cells without harming normal cells.

 

In addition to the human papillomavirus (HPV) vaccine, which is a well-known preventive cancer vaccine, the world’s first and only cancer treatment vaccine approved by the U.S. Food and Drug Administration (FDA) is Provenge (sipuleucel-T). This vaccine realizes the idea of ​​using the patient’s own immune system to attack cancer cells for the first time.

 

The overall survival rate after 2 years of follow-up is 80%! Universal cancer vaccine UV1 was granted Fast Track qualification by FDA

On October 21, the FDA has approved the universal cancer vaccine UV1 combined with checkpoint inhibitors for fast-track designation for patients with unresectable or metastatic melanoma, as the PD-1 monoclonal antibody pembrolizumab (K drug, pembrolizumab) or CTLA-4 monoclonal antibody ipilimumab add-on therapy.

 

Tumor vaccine UV1: 50% of patients survive for more than 5 years!

 

The FDA’s decision is based on the Phase I clinical trial data of two UV1 combined checkpoint inhibitors:

In the data released on October 13, UV1 combined with pembrolizumab as the first-line treatment of advanced melanoma proved to be safe, and the early efficacy data is very promising!

  1. The objective response rate (ORR) was 57%, and 30% of the patients achieved complete remission (CR) or the tumor disappeared completely.
  2. During the 24-month follow-up, 80% of patients survived. As mentioned earlier, the median progression-free survival of these patients was 18.9 months.
  3. The 24-month follow-up data has advantages over the earlier large-scale pembrolizumab study alone, which showed an overall survival rate of 58% after 24 months, and a median progression-free survival rate of 5.5 to 11.6 months.

In the second cohort, 90% of patients were still alive after one year, and the tumor progression was similar.

 

Peer-reviewed data published in Frontiers of Immunology in May 2021 proved that UV1 combined with ipilimumab is safe and has significant long-term efficacy in the treatment of advanced melanoma, with an objective response rate (ORR) of 33% and a 5-year overall survival rate (OS) of 50%.

 

Currently, UV1 combined checkpoint inhibitors are undergoing four phase II clinical trials to treat unresectable or metastatic melanoma, ovarian cancer, head and neck squamous cell carcinoma, and malignant pleural mesothelioma.

 

The data also shows that the combination of UV1 and Keytruda is not only safe but also well tolerated. Adverse events are mainly limited to low-level effects, mainly injection site reactions.

UV1 is a peptide-based vaccine that expands T cells, which has the potential to increase the breadth and diversity of the immune response to all parts of the tumor. As a “universal” therapeutic cancer vaccine, the efficacy of UV1 has been fully verified in a total of 82 patients in 4 phase 1 clinical trials, and its safety and tolerability are also very good.

 

 

Tumor vaccine UV1: 50% of patients survive for more than 5 years!

(source:internet, reference only)


Disclaimer of medicaltrend.org